Hydrocarbons, Fluorinated

• 

  Subject Areas on Research

  • 18F-EF5 PET imaging as an early response biomarker for the hypoxia-activated prodrug SN30000 combined with radiation treatment in a non-small cell lung cancer xenograft model. 
  • A simplified synthesis of the hypoxia imaging agent 2-(2-Nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-[(18)F]pentafluoropropyl)-acetamide ([18F]EF5). 
  • Absence of biochemical evidence for renal and hepatic dysfunction after 8 hours of 1.25 minimum alveolar concentration sevoflurane anesthesia in volunteers. 
  • An efficient synthesis of fluorinated azaheterocycles by aminocyclization of alkenes. 
  • Assessment of low-flow sevoflurane and isoflurane effects on renal function using sensitive markers of tubular toxicity. 
  • Biotransformation of L-cysteine S-conjugates and N-acetyl-L-cysteine S-conjugates of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A) in human kidney in vitro: interindividual variability in N-acetylation, N-deacetylation, and beta-lyase-catalyzed metabolism. 
  • Cellular toxicity associated with exposure to perfluorinated carboxylates (PFCAs) and their metabolic precursors. 
  • Clinical experience with substance P receptor (NK1) antagonists in depression. 
  • Comparison of Amsorb, sodalime, and Baralyme degradation of volatile anesthetics and formation of carbon monoxide and compound a in swine in vivo. 
  • Comparison of the Hypoxia PET Tracer (18)F-EF5 to Immunohistochemical Marker EF5 in 3 Different Human Tumor Xenograft Models. 
  • Compound A uptake and metabolism to mercapturic acids and 3,3,3-trifluoro-2-fluoromethoxypropanoic acid during low-flow sevoflurane anesthesia: biomarkers for exposure, risk assessment, and interspecies comparison. 
  • Cytotoxicity of S-conjugates of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl) vinyl ether (Compound A) in a human proximal tubular cell line. 
  • Dose-dependent metabolism of fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A), an anesthetic degradation product, to mercapturic acids and 3,3,3-trifluoro-2-(fluoromethoxy)propanoic acid in rats. 
  • Evaluation of Maternal, Embryo, and Placental Effects in CD-1 Mice following Gestational Exposure to Perfluorooctanoic Acid (PFOA) or Hexafluoropropylene Oxide Dimer Acid (HFPO-DA or GenX). 
  • Evidence for metabolism of fluoromethyl 2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A), a sevoflurane degradation product, by cysteine conjugate beta-lyase. 
  • Gene expression profiling of nephrotoxicity from the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether ("compound A") in rats. 
  • Glutathione S-conjugation of the sevoflurane degradation product, fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A) in human liver, kidney, and blood in vitro. 
  • Hypoxia in melanoma: using optical spectroscopy and EF5 to assess tumor oxygenation before and during regional chemotherapy for melanoma. 
  • Identification in rat bile of glutathione conjugates of fluoromethyl 2,2-difluoro-1-(trifluoromethyl)vinyl ether, a nephrotoxic degradate of the anesthetic agent sevoflurane. 
  • In vivo imaging using a copolymer phased array. 
  • Long-duration low-flow sevoflurane and isoflurane effects on postoperative renal and hepatic function. 
  • Low-flow sevoflurane compared with low-flow isoflurane anesthesia in patients with stable renal insufficiency. 
  • Luminescent Difluoroboron β-Diketonate PLA-PEG Nanoparticle. 
  • Nephrotoxicity of sevoflurane compound A [fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether] in rats: evidence for glutathione and cysteine conjugate formation and the role of renal cysteine conjugate beta-lyase. 
  • P450-dependent and nonenzymatic human liver microsomal defluorination of fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A), a sevoflurane degradation product. 
  • Pharmacovigilance and safety aspects of sevoflurane. 
  • Polyfluorinated compounds in serum linked to indoor air in office environments. 
  • Renal cysteine conjugate beta-lyase and compound A nephrotoxicity: minimal evidence for an association. 
  • Reply: Pharmacokinetic and Pharmacodynamic Modifiers of EF5 Uptake and Binding. 
  • Role of cytochrome P4503A in cysteine S-conjugates sulfoxidation and the nephrotoxicity of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A) in rats. 
  • Role of renal cysteine conjugate beta-lyase in the mechanism of compound A nephrotoxicity in rats. 
  • Role of the renal cysteine conjugate beta-lyase pathway in inhaled compound A nephrotoxicity in rats. 
  • Safety of low-flow sevoflurane anesthesia in patients with chronically impaired renal function is not proven. 
  • Sulfoxidation of cysteine and mercapturic acid conjugates of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A). 
  • [Compound A: toxicology and clinical relevance].